Company: TEM
Filing Date: 2025-08-27
Form Type: 424B7
Source: 0001193125-25-189854
Chunk: 23

Company: Tempus AI, Inc.
Filing Date: 2025-08-27
Form: 424B7
Chunk 23
---
us and any applicable prospectus supplement contain forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained or incorporated in this prospectus and any applicable prospectus supplement, including statements regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations, are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will” or “would” or the negative of these words or other similar terms or expressions. Within the meaning of Section 27A of the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), these forward-looking statements include, but are not limited to, statements concerning the following:

| • |     | the evolving treatment paradigm for cancer, including physicians’ use of molecular data and targeted 
 oncology therapeutics and the market size for our current and future products;                       |

| • |     | our ability to expand our business beyond oncology into new disease areas; |

| • |     | estimates of our addressable market and our expectations regarding our revenue, expenses, capital requirements 
 and operating results;                                                                                         |

| • |     | our ability to develop new products and services, including our goals and strategy regarding development and 
 commercialization of our AI Applications product line;                                                       |

| • |     | our ability to maintain and grow our datasets, including in new disease areas and geographies; |

| • |     | any expectation that the growth of our datasets will improve the quality of our products and services and 
 accelerate their adoption;                                                                                |

| • |     | our ability to capture, aggregate, analyze or otherwise utilize genomic data in new ways and in additional 
 diagnostic modalities;                                                                                     |

| • |     | any expectation that we will continue to commercialize de-identified 
 records and license them to multiple customers;                      |

| • |     | the acceptance of our publications in peer-reviewed journals or of our presentations at scientific and medical 
 conference presentations;                                                                                      |

| • |     | the implementation of our business model and strategic plans for our products, technologies and businesses; |

| • |     | competitive companies and technologies and